BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

133 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The BAP1 trial will examine the blood of patients diagnosed with choroidal nevi or uveal melanoma for a germline BAP1 mutation and other genetic markers associated with developing malignancy as well as additional sequencing of the uveal melanoma genome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical and Histopathologic Characteristics of BAP1 Mutations

NCT01773655

Malignant Pleural Mesothelioma (MPM) Choroidal Nevus Primary Uveal Melanoma (UM) +3 more

COMPLETED

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

NCT03830229

Mesothelioma Families

RECRUITING

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

NCT04792463

Uveal Melanoma Cutaneous Melanoma BAP1 Gene Mutation +5 more

RECRUITING

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

NCT05223218

Breast Cancer Ovarian Cancer Pancreatic Cancer +2 more

UNKNOWN

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

NCT04431024

Familial Cancer BRCA1-Associated Protein-1 (BAP1) Mutations Tumor Predisposition Syndrome (TPDS) +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A germline BAP1 mutation predisposes a person to developing uveal melanoma and other cancers. If a mutation is discovered, it changes the potential approach to managing the nevus. In the presence of a known genomic change associated with aggressive disease, closer follow up and more aggressive treatment could preserve the patient's vision and prevent micrometastatic spread. This new screening technique will be able to extend the length and quality of life of patients with more frequent targeted cancer screens.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Choroidal Nevi, Uveal Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

any person with choroidal nevi

* Willingness to provide signed informed consent
* Age \> 18 years
* Diagnosis of choroidal nevi or uveal melanoma

Threre are no exclusionary criteria for this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No